


In the Claims:

1. (original) A compound of the general formula (I)



in which

X represents a hydrogen or halogen atom,

R₁ represents a hydrogen atom or a (C₁-C₄)alkyl group,

R₂ and R₃ each independently of one another represent a hydrogen atom or a (C₁-C₄)alkyl group, or else R₂ and R₃, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C₁-C₄)alkylpiperazinyl group, and

Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more (C₁-C₄)alkyl and/or (C₁-C₄)alkoxy groups,

in the form of the base or an addition salt with acids, or in the hydrate or solvate form.

2. (currently amended) The compound according to claim 1, ~~characterized in that~~ wherein X represents a halogen atom.

3. (currently amended) The compound according to claim 1 ~~or 2, characterized in that~~ wherein R₁ represents a (C₁-C₄)alkyl.


4. (currently amended) The compound according to ~~any one of claims 1 to 3,~~ characterized in that claim 1 wherein R₂ and R₃, each independently of one another, represent a (C₁-C₄)alkyl group or else R₂ and R₃, together with the nitrogen atom bearing them, form a pyrrolidinyl or 4-(C₁-C₄)alkylpiperazinyl group.

5. (currently amended) The compound according to ~~any one of claims 1 to 4,~~ characterized in that claim 1 wherein Het represents a heteroaromatic group of pyridinyl

type which may carry one or more halogen atoms and/or one or more (C₁-C₄)alkyl and/or (C₁-C₄)alkoxy groups.

6. **(currently amended)** The compound according to ~~any one of claims 1 to 5, characterized in that~~ claim 1 wherein X represents a chlorine atom and R₁ represents a methyl group.

7. **(currently amended)** A process for preparing a compound of general formula (I),



in which


X represents a hydrogen or halogen atom,

R₁ represents a hydrogen atom or a (C₁-C₄)alkyl group,

R₂ and R₃ each independently of one another represent a hydrogen atom or a (C₁-C₄)alkyl group, or else R₂ and R₃, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C₁-C₄)alkylpiperazinyl group, and

Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more (C₁-C₄)alkyl and/or (C₁-C₄)alkoxy groups,

~~characterized in that~~ wherein the compound of general formula (IV),




in which

X, R₁, R₂ and R₃ are as defined above,

R' represents a (C₁-C₄)alkyl group,

is reacted, in a polar solvent in the presence of acid, with a heteroarylhydrazine.


8. **(currently amended)** The process according to claim 7, ~~characterized in that~~ wherein the compound of general formula (IV),



in which

X, R₁, R₂, R₃ and R' are as defined above

is prepared by reacting a compound of general formula (III),




in which

X, R₁ and R' are as defined above,

R'' represents a (C₁-C₄)alkyl group,

with an amine of general formula HNR₂R₃, in which R₂ and R₃ are as defined above, in the presence of a catalyst such as 4-(dimethylamino)pyridine.

9. **(original)** A process for preparing a compound of general formula (I),



in which

X represents a hydrogen or halogen atom,


R_1 represents a hydrogen atom or a (C₁-C₄)alkyl group,

R_2 and R_3 each independently of one another represent a hydrogen atom or a (C₁-C₄)alkyl group, or else R_2 and R_3 , together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C₁-C₄)alkylpiperazinyl group, and

Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more (C₁-C₄)alkyl and/or (C₁-C₄)alkoxy groups,

comprising the step consisting in

carrying out an N-heteroarylation reaction on a compound of general formula (V),




in which

X, R_1 , R_2 and R_3 are as defined above,

in the presence of a heteroaryl halide, or else of a heteroarylboronic acid derivative and of a metal salt such as a copper salt.


10. **(currently amended)** The process according to claim 9, ~~characterized in that~~ wherein compound of general formula (V),



in which

X, R_1 , R_2 and R_3 are as defined above,

is prepared by reacting a compound of general formula (IV),




in which

X, R₁, R₂, R₃ are as defined above,

R' represents a (C₁-C₄)alkyl group,

with hydrazine by heating in a solvent such as toluene in the presence of a catalytic amount of acid.

11. **(original)** A compound of the general formula (III)




in which

X represents a hydrogen or halogen atom,

R₁ represents a hydrogen atom or a (C₁-C₄)alkyl group,

R' and R'', each independently of one another, represent a (C₁-C₄)alkyl group.

12. **(original)** A compound of the general formula (IV)



in which


X represents a hydrogen or halogen atom,

R₁ represents a hydrogen atom or a (C₁-C₄)alkyl group,

R' represents a (C₁-C₄)alkyl group,

R₂ and R₃, each independently of one another, represent a hydrogen atom or a (C₁-C₄)alkyl group, or else R₂ and R₃, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C₁-C₄)alkylpiperazinyl group.

13. **(original)** A compound of the general formula (V)



in which

X represents a hydrogen or halogen atom,

R₁ represents a hydrogen atom or a (C₁-C₄)alkyl group,

R₂ and R₃, each independently of one another, represent a hydrogen atom or a (C₁-C₄)alkyl group, or else R₂ and R₃, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C₁-C₄)alkylpiperazinyl group.

14. **(cancelled)**

15. **(currently amended)** A pharmaceutical composition ~~characterized in that it comprises~~ comprising at least one compound of formula (I) according to ~~any one of claims 1 to 6, claim~~ 1 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

16. **(new)** The compound according to claim 2 wherein R₁ represents a (C₁-C₄)alkyl.

17. **(new)** The compound according to claim 2 wherein R₂ and R₃, each independently of one another, represent a (C₁-C₄)alkyl group or else R₂ and R₃, together with the nitrogen atom bearing them, form a pyrrolidinyl or 4-(C₁-C₄)alkylpiperazinyl group.

18. **(new)** The compound according to claim 3 wherein R_2 and R_3 , each independently of one another, represent a (C₁-C₄)alkyl group or else R_2 and R_3 , together with the nitrogen atom bearing them, form a pyrrolidinyl or 4-(C₁-C₄)alkylpiperazinyl group.
19. **(new)** The compound according to claim 2 wherein Het represents a heteroaromatic group of pyridinyl type which may carry one or more halogen atoms and/or one or more (C₁-C₄)alkyl and/or (C₁-C₄)alkoxy groups.
20. **(new)** The compound according to claim 3 wherein Het represents a heteroaromatic group of pyridinyl type which may carry one or more halogen atoms and/or one or more (C₁-C₄)alkyl and/or (C₁-C₄)alkoxy groups.
21. **(new)** The compound according to claim 4 wherein Het represents a heteroaromatic group of pyridinyl type which may carry one or more halogen atoms and/or one or more (C₁-C₄)alkyl and/or (C₁-C₄)alkoxy groups.
22. **(new)** The compound according to claim 2 wherein X represents a chlorine atom and R_1 represents a methyl group.
23. **(new)** The compound according to claim 3 wherein X represents a chlorine atom and R_1 represents a methyl group.
24. **(new)** The compound according to claim 4 wherein X represents a chlorine atom and R_1 represents a methyl group.
25. **(new)** The compound according to claim 5 wherein X represents a chlorine atom and R_1 represents a methyl group.
26. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

27. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 3 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
28. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 4 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
29. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 5 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
30. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 6 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
31. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 16 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
32. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 17 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
33. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 18 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
34. **new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

35. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 20 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
36. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 21 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
37. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 22 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
38. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 23 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
39. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 24 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
40. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 25 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.
41. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.
42. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.

43. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.

44. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.

45. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 5.

46. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 6.

47. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 16.

48. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 17.

49. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 18.

50. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 19.

51. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 20.

52. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 21.

53. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 22.

54. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 23.

55. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 24.

56. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 25.